Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation, alleging that the company misled investors regarding the impact of the termination of its acquisition by Amazon and the effectiveness of its restructuring plan [1][2][3]. Group 1: Allegations and Company Actions - iRobot and Amazon mutually agreed to terminate the acquisition in January 2024, yet iRobot claimed confidence in its ability to operate successfully as a standalone company [2][3]. - Following the acquisition termination, iRobot announced a restructuring plan, referred to as "iRobot Elevate," aimed at stabilizing the company and focusing on profitability and market share growth [2][3]. - On March 12, 2025, iRobot reported disappointing financial results for Q4 and the full year of 2024, leading to a significant drop in stock price by $3.255 per share, or 51.58%, closing at $3.055 per share [2][3]. Group 2: Financial Stability Concerns - The lawsuit alleges that iRobot overstated the effectiveness of its restructuring plan and that it was unlikely to operate profitably as a standalone entity, raising doubts about its ability to continue as a going concern [3].

Core Viewpoint - Robbins LLP is investigating Kindercare Learning Companies, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1]. Group 1: Company Overview - Kindercare Learning Companies, Inc. provides early childhood education and care services in the United States [1]. Group 2: Legal Investigation - The investigation by Robbins LLP aims to determine if there were any violations of securities laws by Kindercare's officers and directors [1]. - Shareholders who have lost money in their investment in Kindercare are encouraged to contact Robbins LLP for more information about their rights [2]. Group 3: Robbins LLP Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [3].

Group 1 - Robbins LLP is investigating BellRing Brands, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] - BellRing Brands manufactures and sells nutrition products both in the U.S. and internationally [1] - Shareholders who have lost money in their investment in BellRing Brands are encouraged to contact Robbins LLP for more information about their rights [1] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [2] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [2] Group 3 - Shareholders can sign up for alerts regarding class action settlements or corporate executive wrongdoing related to BellRing Brands [3]

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation, alleging that the company misled investors about its business prospects and financial outlook during the specified period [1][2]. Allegations - The complaint claims that Centene's management created a false impression of having reliable information regarding projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [2]. - A preliminary analysis indicated that over two-thirds of Centene's marketplace share showed disappointing enrollment figures and increased morbidity, contradicting the company's optimistic reports [2]. Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its overall market growth across 22 states was lower than anticipated, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share on July 2, 2025, marking a decline of over 40% [3].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly misleading investors about its business prospects during the pandemic [1][2]. Group 1: Allegations - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [2]. - It is alleged that the company downplayed the severity of issues affecting its business and the necessary changes to address these issues [2]. - The complaint states that Petco overstated its ability to achieve sustainable and profitable growth, leading to a decline in stock price when the truth was revealed [2]. Group 2: Class Action Participation - Investors who purchased Petco securities between January 14, 2021, and June 5, 2025, may be eligible to participate in the class action [1][3]. - Shareholders interested in serving as lead plaintiffs can contact the firm, but participation is not required to be eligible for recovery [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is successful [4].

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Group 1 - A class action has been filed against Reddit, Inc. on behalf of investors who purchased securities between October 29, 2024, and May 20, 2025 [1] - The allegations include that Reddit misled investors about reduced user traffic due to changes in Google Search's algorithm and features, which led to a significant decline in traffic to the Reddit website [2] - The complaint states that the defendants were aware that increased search queries for "Reddit" were due to users finding answers directly on Google, rather than intending to visit Reddit, which contributed to the misleading public statements [2] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP for more information on serving as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]